No to obesity!

The battle of titans in the obesity and GLP-1 drug market is only intensifying. And this is no longer just competition between pharmaceutical companies, but a full-scale race for one of the fastest-growing segments of medicine.

A fresh reason for discussion is the ORION study data from Novo Nordisk. Essentially, this is a careful but quite clear response to the promotion of a new drug from Eli Lilly. And this response comes not in advertising slogans, but in numbers that the market usually takes far more seriously.

Context matters here. A new oral drug, Foundayo, has entered the scene and has already received approval from the FDA. This is a direct competitor to Wegovy, but with a different key advantage – its form of administration. If the market was previously being trained to accept injections, players are now betting on pills. And that represents a completely different level of convenience and, as a result, potential mass demand.

At the same time, the market itself is growing so rapidly that the classic “winner-takes-all” logic no longer applies. We are talking about tens of billions of dollars, and according to forecasts, this is only the beginning. In such conditions, companies begin to compete not only with products, but also with the interpretation of data. In other words, a quiet information war begins, where each study is also a tool for influencing investors.

Looking at the ORION results, the picture appears quite strong in favor of Novo Nordisk. The tablet version of Wegovy showed approximately 3-3.2% greater weight loss. On paper, the difference may seem small, but in clinical practice it is meaningful. In addition, Foundayo has a significantly higher probability of treatment discontinuation – about four times higher. And when it comes to gastrointestinal side effects, the gap is even wider: the risk of stopping treatment is about fourteen times higher.

At this point, one would usually expect a clear market reaction. But it did not happen. And that is where things get interesting. The reason is that Foundayo is playing a different strategy. Its main advantage is convenience. The drug can be taken without strict timing or conditions, which for the mass user is often more important than a few percentage points of effectiveness. In real life, people choose not the perfect solution, but the one that is easier to live with.

There is also the manufacturing factor. Tablets are easier to scale than injectable drugs. This means faster entry into the mass market and potentially broader coverage. For investors, that is an entirely different equation.

It is not surprising that analysts, despite clinical nuances, still project billions in revenue for the new product as early as 2026. In essence, the market is voting not only for effectiveness, but also for accessibility.

Looking more broadly, it becomes clear that this is not a duel in the classical sense. It is the formation of a new pharmaceutical segment where different approaches can successfully coexist. Eli Lilly is betting on scale, convenience, and mass adoption. Novo Nordisk is betting on clinical effectiveness and proven results.

That is why the idea of a “single winner” looks outdated here. The market is expanding so quickly that there is room for multiple major players. Moreover, oral GLP-1 forms could capture up to 20-30% of the entire segment in the coming years. This is a natural stage of evolution: innovation first appears in a complex form, then becomes simplified and mass-market.

From an investment perspective, this is one of the strongest structural trends of the decade. Demand for obesity drugs is growing not because of fashion, but due to fundamental factors – demographics, lifestyle, and the rise of chronic diseases.

Within this logic, both companies remain key beneficiaries. And perhaps the main conclusion is quite simple: while the market is still forming, the winner is not the one who “destroys” the competitor, but the one who occupies its niche faster and holds it. Everything else is no longer a battle, but a long and very profitable marathon.